Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Inhalation Drug Delivery Devices Market $17.6 Billion by 2027

The global market for inhalation drug delivery devices predicted to attain $17.6 billion by 2027, growing at CAGR 2.8% over the forecast period, driven by rising prevalence of asthma, cystic fibrosis, and chronic obstructive pulmonary diseases.

Global Inhalation Drug Delivery Devices Market
  • According to global asthma report, as many as 334 million people have asthma, and that the burden of disability is high.
    • In 2018, there were 111.6 million people living with asthma and COPD worldwide, with COPD accounting for 54% of the total cases.
      • Over the next two decades, prevalence rates are expected to rise at 7% in total asthma cases and 23% in total COPD cases.
  • According to WHO estimates, 65 million people have moderate to severe COPD.
    • Currently, an estimated 300 million people worldwide have asthma and up to 10% of adults older than 40 years of age may have COPD, with perhaps millions remaining undiagnosed.
      • Asthma cases in the U.S., Europe and Japan are expected to rise from 51.3 million in 2016 to 54.9 million by 2036.
      • By 2038, COPD cases in the US, the five major European countries (5EU: Germany, UK, Italy, Spain and France) and Japan will reach an estimated 73.6 million total cases.

Respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease are classical therapeutic areas of the pulmonary sector. Asthma and chronic obstructive pulmonary disease (COPD) represent the leading chronic respiratory diseases in the world, owing to their high prevalence and high burden on the health system.

  • Asthma prevalence is still increasing in both developed and developing countries, for different reasons.
    • The majority of asthma patients are well managed using existing technologies such as inhalers as well as injectables and oral biologics.
      • While most innovation in asthma treatment products has been focused on biologics and injectables, triple-combination therapies containing ICS, long-acting beta antagonist (LABA) and LAMA medications in a single device are gaining traction.

The global inhalation drug delivery devices market research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global inhalation drug delivery devices market segmented by product [dry powder inhalers, metered dose inhalers (pressurized metered dose inhalers, spacers for MDIs, breath-actuated MDIs), nebulizers]; by indication (asthma, chronic obstructive pulmonary disease, cystic fibrosis, idiopathic pulmonary fibrosis, others); and geography. Pipeline analysis by product (title, indication, intervention, sponsor, developmental phase, as well as marketed products by drug, manufacturer and indication has been provided.

  • Inhalation drug delivery covers many different types of devices: nebulizers, pressurized metered dose inhalers (MDIs), breath-activated inhalers (including dry powder inhalers), and emerging novel delivery systems. The number of inhaler devices available in the market for inhaled therapies has increased significantly in the past decade.
  • There are two types of nebulizers, jet and ultrasonic, that differ in the force used to generate the aerosol from the respective liquid.

Some of the newest nebulizer models in the market include breath-enhanced jet nebulizers such as the Pari LC or Respironics SideStream; breath-actuated nebulizers such as the AeroEclipse; vibrating mesh nebulizers such as Pari eFlow rapid, Omron U22, AKITA2, APIXNEB.

  • The pressurized metered-dose inhalers (pMDIs) can be classified as breath-actuated or coordination devices. Breath-actuated pMDIs, such as the Easibreathe, are designed to address the problem of poor coordination between inhaler actuation and patient’s breathe.
  • Spacers and valved holding chambers (VHCs) are used with pMDIs to increase the efficiency of aerosol delivery.
  • Multi-dose liquid inhalers (Respimat Soft Mist inhaler) combines the advantages of pMDIs and nebulizers.
  • The dry powder inhalers (DPIs) are portable devices that require minimum patient coordination between breathing and actuation of the device to deliver powder medications.
  • Thermal vaporization aerosol devices such as STACCATO uses heat to vaporize a thin film of the drug, which later condenses in the lungs into droplets or particles depending on the nature of the drug.

The global inhalation drug delivery devices market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the North America region accounted for the highest share, followed by the Europe region of the global market.
    • The key driving factors for growth include generic erosion, increasing incidence of pulmonary diseases and an increasing awareness of the inherent benefits offered by introduction of novel products.
      • While in developed countries the increase in asthma prevalence is mainly related to their lifestyle (exposure to indoor allergens, low levels of exercise, diets that are poor in antioxidants and obesity), in developing countries the increased prevalence is mainly related to the air pollution and high rates of smoking.

In addition, the global inhalation drug delivery products market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

  • The inhalation drug delivery devices market is dominated by three major players: GlaxoSmithKline plc, AstraZeneca plc and Boehringer Ingelheim International GmbH.
  • While several of these companies are facing competition from generics, the high cost of developing inhalation products leads to low price discounts for generic alternatives.
    • Consequently, some patients will continue to use their branded products rather than switching to a generic.
  • The introduction of triple-combination products, which eliminates the need for patients to carry multiple devices, is also driving the inhalation drug-delivery devices market.
    • GlaxoSmithKline led the market based on sales of its Advair, Anoro Ellipta, Breo Ellipta, Incruse Ellipta and Trelegy Ellipta products.
    • AstraZeneca ranked second with sales of its Bevespi Aerosphere, Duaklir Pressair, Symbicort and Tudorza Pressair products.
    • Boehringer Ingelheim ranked third with ales of its Spiriva, Stiolto Respimat and Striverdi Respimat devices.

Major competitors operating in the global market for inhalation drug delivery devices and profiled in this report include AptarGroup, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Chiesi Farmaceutici SpA, GlaxoSmithKline plc, Koninklijke Philips NV, Merck & Co, Inc., Monaghan Medical Corporation, Novartis AG, OMRON Corporation, PARI international, Vectura Group Plc (Activaero GmbH/SkyePharma plc), Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

  • Product / Technology
    • Dry Powder Inhalers (DPIs)
    • Metered Dose Inhalers (MDIs)
      • Pressurized MDIs
      • Breath-actuated MDIs
      • Spacers for MDIs
    • Nebulizers
  • Indication
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Cystic Fibrosis (CF)
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Others (Exercise Induced Bronchospasm, Acute Respiratory Distress Syndrome, Pulmonary Arterial Hypertension, Pulmonary Metastases, Sinusitis, Osteoarthritis, Ventilator Associated Pneumonia)
  • Pipeline Analysis, by Product (Title, Indication, Intervention, Sponsor, Phase)
    • Dry Powder Inhalers (DPIs)
    • Pressurized MDIs
    • Nebulizers
  • Marketed Products, by Drug, Manufacturer, Indication
    • Dry Powder Inhalers (DPIs)
    • Pressurized MDIs
    • Nebulizers
  • Geography
  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  • Asia Pacific (Japan, China, India, Rest of APAC
  • Latin America (Brazil, Mexico, Rest of LA)
  • Rest of the World
  • Company Profiles
    • AptarGroup, Inc.
    • AstraZeneca plc
    • Boehringer Ingelheim GmbH
    • Chiesi Farmaceutici S.p.A.
    • GlaxoSmithKline Plc
    • Koninklijke Philips NV (Respironics, Inc.)
    • Merck & Co, Inc.
    • Monaghan Medical Corporation
    • Novartis AG
    • OMRON Corporation
    • PARI international
    • Vectura Group plc (Activaero GmbH/SkyePharma plc)
    • Sunovion Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]